Zenas BioPharma Statistics
Total Valuation
Zenas BioPharma has a market cap or net worth of $705.35 million. The enterprise value is $431.39 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenas BioPharma has 42.11 million shares outstanding. The number of shares has increased by 2,050.40% in one year.
| Current Share Class | 42.11M |
| Shares Outstanding | 42.11M |
| Shares Change (YoY) | +2,050.40% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 50.45% |
| Float | 20.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.14 |
| Forward PS | n/a |
| PB Ratio | 2.94 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 28.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.23, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.23 |
| Quick Ratio | 5.16 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -88.40% and return on invested capital (ROIC) is -58.80%.
| Return on Equity (ROE) | -88.40% |
| Return on Assets (ROA) | -47.94% |
| Return on Invested Capital (ROIC) | -58.80% |
| Return on Capital Employed (ROCE) | -78.84% |
| Revenue Per Employee | $115,385 |
| Profits Per Employee | -$1.36M |
| Employee Count | 130 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zenas BioPharma has paid $244,000 in taxes.
| Income Tax | 244,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.48 |
| 200-Day Moving Average | 10.83 |
| Relative Strength Index (RSI) | 64.39 |
| Average Volume (20 Days) | 127,130 |
Short Selling Information
The latest short interest is 5.23 million, so 12.41% of the outstanding shares have been sold short.
| Short Interest | 5.23M |
| Short Previous Month | 5.07M |
| Short % of Shares Out | 12.41% |
| Short % of Float | 24.94% |
| Short Ratio (days to cover) | 22.79 |
Income Statement
In the last 12 months, Zenas BioPharma had revenue of $15.00 million and -$177.01 million in losses. Loss per share was -$5.31.
| Revenue | 15.00M |
| Gross Profit | -145.63M |
| Operating Income | -189.10M |
| Pretax Income | -54.46M |
| Net Income | -177.01M |
| EBITDA | -189.00M |
| EBIT | -189.10M |
| Loss Per Share | -$5.31 |
Full Income StatementBalance Sheet
The company has $273.28 million in cash and $1.01 million in debt, giving a net cash position of $272.27 million or $6.47 per share.
| Cash & Cash Equivalents | 273.28M |
| Total Debt | 1.01M |
| Net Cash | 272.27M |
| Net Cash Per Share | $6.47 |
| Equity (Book Value) | 239.63M |
| Book Value Per Share | 5.69 |
| Working Capital | 225.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$148.41 million and capital expenditures -$92,000, giving a free cash flow of -$148.50 million.
| Operating Cash Flow | -148.41M |
| Capital Expenditures | -92,000 |
| Free Cash Flow | -148.50M |
| FCF Per Share | -$3.53 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,260.67% |
| Pretax Margin | -1,178.42% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zenas BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,050.40% |
| Shareholder Yield | -2,050.40% |
| Earnings Yield | -25.16% |
| FCF Yield | -21.10% |
Dividend DetailsAnalyst Forecast
The average price target for Zenas BioPharma is $32.29, which is 92.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.29 |
| Price Target Difference | 92.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenas BioPharma has an Altman Z-Score of 1.91 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 2 |